KYTX NASDAQ
Credit Risk of going bust: higher than 71% of companies Debt: 9.2% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.07 (down 99%), Kyverna Therapeutics, Inc. would be worth roughly what it owes.
Total debt $33.0M against a stock market value of $325.9M.
Distance to default 3.36 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $12.4M (short-term plus half of long-term), stock volatility 91.3%; Altman Z'' -3.38. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Emeryville, CA 94608
US
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and lupus nephritis, as well as multiple sclerosis and systemic sclerosis. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CLARK IAN T | A-Award | 5,093 | — | 2026-05-27 |
| CLARK IAN T | A-Award | 20,582 | $8.59 | 2026-05-27 |
| Cohen Fred E | A-Award | 5,093 | — | 2026-05-27 |
| Cohen Fred E | A-Award | 20,582 | $8.59 | 2026-05-27 |
| SEIDENBERG BETH C | A-Award | 5,093 | — | 2026-05-27 |